For Immediate
Release
7 December 2009


          ReGen Therapeutics Plc ('ReGen' or 'the Company')

                      RESULT OF GENERAL MEETING


ReGen Therapeutics Plc (AIM:RGT) are pleased to announce that at the
General Meeting held today all Resolutions were passed.

The Board also felt it was appropriate to give an update on the
encouraging position of the Company at this date and reported to the
meeting as follows:


 1. Turkey

We are pleased to report that Eczacibasi now expect the Government to
give final labelling approval for their 'Dyna' version of
Colostrinin(TM) by the end of December 2009 and for the full
commercial launch in Turkey to take place in February 2010.  We would
remind Shareholders of the financial terms of the Turkish agreement
which are:  On Government approval, Eczacibasi will pay ReGen a
$50,000 milestone payment and net revenues to ReGen from Eczacibasi,
pursuant to the minimum annual purchase commitments in the
Distribution Agreement, are estimated to be $52,000 in the first
year, after regulatory approval is obtained, and $104,000 in the
second year.

2.         India
ReGen has a Material Transfer Agreement in place with an Indian
company, which is currently working on producing a tablet for the
Indian market.  Should this work be successful it would lead to a
full Licensing and Distribution Agreement being signed for India.  We
would comment that India with a population of 1.1 billion represents
a very significant market where self-medication is a normal feature
of medicine.

3.         South Korea
Following our recent discussions in London with two senior executives
of a major South Korean company, we are now negotiating the final
terms of a contract to distribute Colostrinin(TM) in South Korea.  We
believe this company would have the marketing power to fully exploit
the sales potential of a product based on Colostrinin(TM).

4.         China
Our contacts through a technology transfer company, sponsoring
innovation in China from the UK, has led to us signing a
Confidentiality Agreement with a leading Chinese pharmaceutical
company to explore the possibility of marketing Colostrinin(TM) in
China.  With a population of 1.3 billion, nearly one fifth of the
world's population, China also represents a very significant market
for Colostrinin(TM).  Like India, China also self-medicates and as we
are well aware is an important market for alternative therapies.


5.         Existing Markets
i.          USA and Canada
Development in the USA has not been as rapid as we had hoped but we
believe the takeover of Metagenics by Alticor/Amway, the large
consumer products marketing organisation, will lead to our product
being more widely promoted, outside of the relatively narrow
marketing strategy of the original Metagenics design.  Metagenics
advise us that they are currently working on positioning the product
in the USA and Canada and expect to carry out a substantial relaunch
of the product in 2010.

ii.         Australia
In August 2009 the Australian Quarantine Inspection Service (AQIS)
announced a review of the regulations governing all colostrum-derived
imported goods. In consequence, there are a large number of products,
including new supplies of Colostrinin(TM), currently being held up
awaiting customs clearance.  We understand that Health World
Australia Limited is out of stock of Colostrinin(TM), so are
understandably as frustrated as we are about the inevitable effect
the delay is having on their sales, and are working hard with the
relevant authorities to overcome the problem.

iii.         Poland
Sales in Poland are proceeding as expected at the time of signing the
original Test Marketing Agreement in November 2008.

iv.        Cyprus
Golgi has had a significant marketing campaign in Cyprus despite some
consumers experiencing problems with tablets discolouring.  New
packaging is urgently being developed to address this problem. A new
marketing drive is planned to coincide with its introduction.

v.         UK
MemoryAid was successfully launched in September and we are very
pleased that Colostrinin(TM) is finally available in our home
market.  We understand that PRG Nutraceuticals are now planning a
press campaign to heighten awareness of the product in the wider
market.

6.         Zolpidem
Dr Ralf Clauss presented a study conducted in Pretoria, South Africa
on zolpidem at the 4th International Congress on Brain and Behaviour
on 3 - 6 December 2009 in Thessaloniki, Greece. This study using
SPECT scanning showed that zolpidem significantly improves the
cognitive and motor performance of subjects with brain damage.  This
important finding was sponsored by the South Africans who intend to
do a further study on zolpidem in 2010.  Thus, whilst ReGen is not
spending money on developing the product further the South African
community is providing more and more information to make the case for
a licensing deal. We are also investigating the possibility of
obtaining grant aid to progress the zolpidem project.

We should also point out that both of the companies that we are
dealing with in South Korea and China have expressed interest in
zolpidem.


7.                  Colostrinin(TM) Derived Peptides
Whilst there has been a temporary halt in the development of the
peptides we are discussing further work with the University of Texas
Medical Branch, Galveston and continuing to seek potential licensees
and grant support.

8.         Obesity
We reiterate that a major Global Company is planning to do an animal
study with Colostrinin(TM) in 2010. If successful this may lead to
them licensing rights to develop the ingredient for use in a
'weight-loss' range of products.

For further information please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396
Nick Bealer/David Scott
Alexander David
Tel No 020 7448 9820

---END OF MESSAGE---




This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.


Copyright © Hugin AS 2009. All rights reserved.